Below is for you.
One leading drug currently in mid-stage development is AMG 151, formerly ARRY-403, from Amgen. Amgen is utilizing technology from Array BioPharma's (NASDAQ: ARRY ) glucokinase activator program, which it licensed in 2009. In early-stage trials conducted by Array, AMG 151 demonstrated effective control of glucose levels, and, more interestingly, showed even better effects when combined with existing type 2 diabetes medications metformin or Merck's Januvia and reached maximum efficiency very quickly, after just five to seven days of treatment.
...At your peril. Array is making the turn into a late-stage development company with multiple Phase three indications and partnerships (and potential for more), and significant milestone potential. Considering this, the stock is dirt cheap vis a vis other comparable companies and many with fewer opportunities.